Allyx Therapeutics .

Allyx Therapeutics is a clinical stage biotechnology company based in CT. We are targeting synapse preservation as a disease-modifying approach for treating Alzheimer’s disease. Our lead candidate ALX-001 is an orally bioavailable small molecule drug which acts as a silent allosteric modulator of mGluR5 to selectively block Prion Protein initiated synaptic dysfunction. ALX-001 reversed cognitive impairment and rescued synapse loss in multiple aged transgenic mouse models of AD. The FDA has approved the IND-application for this program with first in human administration of ALX-001 in healthy volunteers currently underway.